(Reuters)
- Drug developer Arrowhead Research Corp said the U.S. Food and Drug
Administration placed the company's experimental hepatitis B treatment
on partial clinical hold, seeking additional data from the drug's
mid-stage study.
The company's shares plunged 22
pct premarket on Monday after the FDA also asked the company to reduce
the dosage of the drug, ARC-520.
The
FDA requested Arrowhead to begin the multiple-dose trial for the drug
at 1mg/kg - much lower than the company's proposed 2 mg/kg and 4 mg/kg.
Read more...Labels: ARC-520, Arrowhead